Adaptate Biotherapeutics

Adaptate Biotherapeutics is an immunotherapy company developing a portfolio of innovative therapeutic antibody products designed to modulate the activity of patients' own cytotoxic γ-δ-T cells in situ. The company’s precisely targeted approach holds the potential to safely and effectively address challenges frequently encountered with current cancer immunotherapies. These antibodies target γ-δ T cells, a unique class of lymphocytes capable of combining the speed of innate immunity with the selectivity of adaptive immune responses.